Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing … Read full Trend Edge analysis →
| Current Price | $15.38 |
|---|---|
| Market Cap | $4.51B |
| Float | 103.5M |
| Shares Outstanding | 282.7M |
| P/E (Forward) | 42.02 |
| Price/Sales (TTM) | 4.97 |
| Profit Margin | 3.75% |
| Operating Margin (TTM) | 2.44% |
| Revenue (TTM) | $907M |
| Dividend Rate | None |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2019 | $417M | $31.0M | $201M | $248M |
| 2020 | $294M | $27.7M | $184M | $254M |
| 2022 | $258M | -$321M | $80.0M | -$246M |
| 2023 | $306M | -$341M | $89.3M | -$261M |
| 2024 | $412M | -$282M | $179M | -$183M |
| 2025 | $812M | -$538M | $539M | $11.4M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Jun 2025 | $181M | -$71.8M |
| Sep 2025 | $217M | $24.3M |
| Dec 2025 | $293M | $82.0M |
| Mar 2026 | $216M | -$510,000 |
| Insider Ownership | 48.5% |
|---|---|
| Institutional Ownership | 56.6% |
| Short Float | 12.3% |
| % of All Funds Holding | 2.20% |
| Number of Funds Holding | 181 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $17.57 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $24.46 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $24.68 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $18.00 | resistance | 1.54x | 0 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 2.55% | 1.45% | 75.00% | 22.61% | -15.32% |
| 1 Day | -6.41% | -6.31% | 50.00% | 5.61% | -18.60% |
| 1 Week | -8.97% | -8.64% | 25.00% | 8.04% | -26.66% |
| 2 Weeks | -4.52% | -7.11% | 50.00% | 17.74% | -21.62% |
| 1 Month | -8.16% | -7.05% | 33.33% | 2.03% | -19.45% |
Next earnings: July 26, 2026 (58 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 56.6%
Total insider ownership: 48.5%
Founder-led management: David Dean Halbert (Chairman, CEO & Founder)
| Total Filings | 7 |
|---|---|
| Net Value | -$18.8M |
| Net Shares Change | -461,210 |
| % of Float | -0.4% |
| C-Suite Filings | 6 |
| Clusters Detected | 1 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Spetzler David Baxley | President | -$13.8M | 2 | 1 buy, 1 sell |
| Denton John Russel | Senior Vice President, General Counsel, and Secretary | -$4.2M | 2 | 2 buy, 1 sell |
| Power Luke Thomas | Senior Vice President, Chief Financial Officer, and Chief Accounting Officer | -$1.5M | 1 | N/A |
| Brille Brian J | Vice Chairman and Executive Vice President | +$630,000 | 1 | 1 buy |
| Vacirca Jeff L | +$501,426.45 | 1 | 1 buy |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2025-06-23 – 2025-06-23 | 3 | 3 | -$17.4M | 3 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-05-11 | Vacirca Jeff L | +$501,426.45 | Transaction at $16.15, now -4.8% | |
| 2025-06-23 | Denton John Russel | Senior Vice President, General Counsel, and Secretary | -$4.3M | Transaction at $19.80, now -22.3% |
| 2025-06-23 | Brille Brian J | Vice Chairman and Executive Vice President | +$630,000 | Transaction at $21.00, now -26.8% |
| 2025-11-10 | Denton John Russel | Senior Vice President, General Counsel, and Secretary | +$100,792.56 | Transaction at $24.09, now -36.2% |
| 2025-11-07 | Spetzler David Baxley | President | +$9,540 | Transaction at $23.85, now -35.5% |
| 2025-06-23 | Spetzler David Baxley | President | -$13.8M | Transaction at $16.10, now -4.5% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Caris Life Sciences, Inc. Common Stock (CAI) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for CAI on Trend Edge →